Arcturus Stock Analysis

ARCT -  USA Stock  

USD 25.32  0.42  1.69%

The big decline in price over the last few months for Arcturus Therapeutics could raise concerns from private investors as the firm it trading at a share price of 25.32 on 735,114 in volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Arcturus Therapeutics or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.19. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Arcturus Therapeutics partners.
Please continue to Trending Equities.

Arcturus Stock Analysis 

 
Refresh
The Arcturus Therapeutics stock analysis report makes it easy to digest most publicly released information about Arcturus Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Arcturus Stock analysis module also helps to analyze the Arcturus Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Arcturus Stock Analysis Notes

About 14.0% of the company shares are held by company insiders. The book value of Arcturus Therapeutics was presently reported as 9.83. The company has Price/Earnings (P/E) ratio of 119.5. Arcturus Therapeutics recorded a loss per share of 7.55. The entity next dividend is scheduled to be issued on the December 5, 2012. The firm had a split on the 16th of November 2017. Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. Arcturus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 118 people. For more info on Arcturus Therapeutics please contact Tord Cederlund at 858 900 2660 or go to https://www.arcturusrx.com.

Arcturus Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Arcturus Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Arcturus Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Arcturus Therapeutics generated a negative expected return over the last 90 days
Arcturus Therapeutics has high historical volatility and very poor performance
Arcturus Therapeutics was previously known as Arcturus Therapeutics Holdings and was traded on NASDAQ Exchange under the symbol ADHD.
The company reported the previous year's revenue of 8.8 M. Net Loss for the year was (196.12 M) with loss before overhead, payroll, taxes, and interest of (48.31 M).
Arcturus Therapeutics currently holds about 413.88 M in cash with (99.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.7.
Arcturus Therapeutics has a frail financial position based on the latest SEC disclosures
Roughly 70.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session - Yahoo Finance

Arcturus Therapeutics Upcoming and Recent Events

Earnings reports are used by Arcturus Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Arcturus Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report7th of March 2022
Next Earnings Report9th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End7th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Arcturus Largest EPS Surprises

Earnings surprises can significantly impact Arcturus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2015-05-06
2015-03-31-0.29-0.260.0310 
2015-08-13
2015-06-30-0.29-0.240.0517 
2018-11-07
2018-09-30-0.35-0.42-0.0720 
View All Earnings Estimates

Arcturus Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Arcturus Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Arcturus Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Arcturus Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
11th of January 2022
Regulation FD Disclosure
View
13th of December 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
16th of November 2021
Financial Statements and Exhibits. Other Events
View
9th of November 2021
Unclassified Corporate Event
View
8th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
1st of November 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
26th of October 2021
Unclassified Corporate Event
View
5th of October 2021
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement
View

Arcturus Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 667.18 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arcturus Therapeutics's market, we take the total number of its shares issued and multiply it by Arcturus Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Arcturus Profitablity

Arcturus Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Arcturus Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Arcturus Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Arcturus Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Arcturus Therapeutics' profitability requires more research than a typical breakdown of Arcturus Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.33) (0.35) 
Return on Average Equity(0.43) (0.46) 
Return on Invested Capital(27.22) (27.94) 
Return on Sales(6.77) (6.95) 

Management Efficiency

The entity has return on total asset (ROA) of (32.41) % which means that it has lost $32.41 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (75.32) %, meaning that it created substantial loss on money invested by shareholders. Arcturus Therapeutics management efficiency ratios could be used to measure how well arcturus therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Assets is likely to drop to -0.35 in 2022. Return on Average Equity is likely to drop to -0.46 in 2022. Arcturus Therapeutics Total Liabilities is comparatively stable at the moment as compared to the past year. Arcturus Therapeutics reported Total Liabilities of 91.89 Million in 2021. Current Liabilities is likely to gain to about 61.4 M in 2022, whereas Liabilities Non Current is likely to drop slightly above 29.3 M in 2022.
Last ReportedProjected for 2022
Book Value per Share 17.58  14.02 
Enterprise Value over EBIT(12.65) (13.65) 
Enterprise Value over EBITDA(12.56) (13.55) 
Price to Book Value 2.41  2.47 
Tangible Assets Book Value per Share 26.98  22.36 
Enterprise Value890.9 M961.3 M
Tangible Asset Value547.9 M591.2 M

Technical Drivers

As of the 25th of January, Arcturus Therapeutics shows the risk adjusted performance of (0.08), and Mean Deviation of 4.19. Arcturus Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down nineteen technical drivers for Arcturus Therapeutics, which can be compared to its rivals. Please confirm Arcturus Therapeutics coefficient of variation, as well as the relationship between the treynor ratio and semi variance to decide if Arcturus Therapeutics is priced correctly, providing market reflects its regular price of 25.32 per share. Given that Arcturus Therapeutics has jensen alpha of (0.70), we suggest you to validate Arcturus Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Arcturus Therapeutics Price Movement Analysis

The output start index for this execution was one with a total number of output elements of sixty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Arcturus Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Arcturus Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Arcturus Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arcturus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arcturus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arcturus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Arcturus Therapeutics Technical and Predictive Indicators

Arcturus Therapeutics Forecast Models

Arcturus Therapeutics time-series forecasting models is one of many Arcturus Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Arcturus Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Arcturus Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Arcturus Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Arcturus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Arcturus Therapeutics. By using and applying Arcturus Stock analysis, traders can create a robust methodology for identifying Arcturus entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(6.69) (6.87) 
Gross Margin 0.90  0.89 
Profit Margin(6.81) (6.99) 
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. Arcturus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 118 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Arcturus Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Fundamental Analysis Now

   

Fundamental Analysis

View fundamental data based on most recent published financial statements
All  Next Launch Module
Please continue to Trending Equities. Note that the Arcturus Therapeutics information on this page should be used as a complementary analysis to other Arcturus Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Shere Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Arcturus Stock analysis

When running Arcturus Therapeutics price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Is Arcturus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcturus Therapeutics. If investors know Arcturus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcturus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Arcturus Therapeutics is measured differently than its book value, which is the value of Arcturus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcturus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Arcturus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcturus Therapeutics' market value can be influenced by many factors that don't directly affect Arcturus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcturus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Arcturus Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcturus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.